Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Common Equity (2016 - 2025)

China Pharma Holdings' Common Equity history spans 16 years, with the latest figure at $22.7 million for Q4 2025.

  • For Q4 2025, Common Equity rose 193.5% year-over-year to $22.7 million; the TTM value through Dec 2025 reached $22.7 million, up 193.5%, while the annual FY2025 figure was $22.7 million, 193.5% up from the prior year.
  • Common Equity reached $22.7 million in Q4 2025 per CPHI's latest filing, up from $8.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $22.7 million in Q4 2025 to a low of $2.8 million in Q3 2022.
  • Average Common Equity over 5 years is $7.0 million, with a median of $6.5 million recorded in 2021.
  • Peak YoY movement for Common Equity: tumbled 58.64% in 2022, then skyrocketed 193.5% in 2025.
  • A 5-year view of Common Equity shows it stood at $6.0 million in 2021, then dropped by 28.71% to $4.3 million in 2022, then surged by 73.77% to $7.5 million in 2023, then grew by 3.93% to $7.7 million in 2024, then surged by 193.5% to $22.7 million in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Common Equity are $22.7 million (Q4 2025), $8.3 million (Q3 2025), and $6.5 million (Q2 2025).